Prognostic Value of Hematologic Indices and Composite Models in Anal Squamous Cell Carcinoma Treated with Image-Guided Chemoradiotherapy
Authors:
Open Access
Abstract
Background: Anal squamous cell carcinoma (ASCC) is a rare malignancy primarily treated with chemoradiotherapy (CRT). This study evaluated outcomes and the prognostic value of simple hematologic indices in patients receiving modern image-guided CRT. Methods: Fifty-five patients with non-metastatic ASCC treated between 2017 and 2025 were retrospectively analyzed. Survival was estimated by Kaplan–Meier methods, and prognostic factors were assessed by log-rank testing and Cox regression. Baseline neutrophil-to-lymphocyte (NLR) and platelet-to-lymphocyte (PLR) ratios were analyzed individually and in combination with nodal status. Results: At a median follow-up of 53.1 months, overall survival reached 90% at 5 years, whereas disease-free survival declined to 51%. Nodal positivity showed a non-significant trend toward poorer DFS. Baseline PLR ≥ 150 was significantly associated with inferior DFS in univariable analysis (HR 5.28, 95% CI 1.12–24.97, p = 0.036), while NLR ≥ 3 showed a borderline effect (p = 0.108). In multivariable models, PLR retained borderline prognostic relevance (p = 0.083), whereas Kaplan–Meier curves indicated non-significant trends (p = 0.129 and 0.055). Integrated models combining nodal status with PLR ± NLR improved risk discrimination: Model A (N + PLR ≥ 150 ± NLR ≥ 3) showed a trend (p = 0.059), and Model B (N + PLR ≥ 150) reached significance (p = 0.021; C-index ≈ 0.68–0.69). Conclusions: Modern CRT achieved excellent OS with acceptable toxicity, though early recurrences limited DFS. Integrating hematologic indices with nodal status provides a pragmatic, cost-effective approach for individualized risk assessment and follow-up in ASCC.Keywords
Funding Information
- Univerzita Karlova v Praze
This publication has 26 references indexed in Scilit:
- Prognostic significance of pre‐treatment immune‐inflammation biomarkers in anal cancer: A study combining real‐world data and a meta‐analysisInternational Journal of Cancer, 2025
- Radiation Therapy for Anal Squamous Cell Carcinoma: An ASTRO Clinical Practice GuidelinePractical Radiation Oncology, 2025
- External validation of a composite bio-humoral index in anal cancer patients undergoing concurrent chemoradiationRadiotherapy and Oncology, 2022
- Intensity modulated radiotherapy for anal canal squamous cell carcinoma: A 16-year single institution experienceClinical and Translational Radiation Oncology, 2021
- RADIANCE – Radiochemotherapy with or without Durvalumab in the treatment of anal squamous cell carcinoma: A randomized multicenter phase II trialClinical and Translational Radiation Oncology, 2020
- Patterns and Predictors of Relapse Following Radical Chemoradiation Therapy Delivered Using Intensity Modulated Radiation Therapy With a Simultaneous Integrated Boost in Anal Squamous Cell CarcinomaInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2020
- RTOG 0529: A Phase 2 Evaluation of Dose-Painted Intensity Modulated Radiation Therapy in Combination With 5-Fluorouracil and Mitomycin-C for the Reduction of Acute Morbidity in Carcinoma of the Anal CanalInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2013
- Concurrent chemotherapy and intensity modulated radiation therapy in the treatment of anal cancer: A retrospective review from a large academic centerPractical Radiation Oncology, 2013
- Intensity‐modulated radiation therapy versus conventional radiation therapy for squamous cell carcinoma of the anal canalCancer, 2011
- Fluorouracil, Mitomycin, and Radiotherapy vs Fluorouracil, Cisplatin, and Radiotherapy for Carcinoma of the Anal CanalJAMA, 2008